11Ketoetio	-24.10	-21.06
5βPdiol	-26.61	-21.58

For the "B" sample [see Document package, p. USADA 0351]:

	True Value	Corrected Value
Androsterone	-27.93	-25.29
Etiocholanolone	-26.58	-23.80
5αAdiol	-31.88	-27.43
5βAdiol	-28.79	-23.69
11Ketoetio	-24.75	-21.78
5βPdiol	-26.16	-21.05

The final step in the analysis of the positivity criteria is stated in WADA Technical Document TD2004EAAS (attached hereto as Exhibit 2), p.3, as follows:

"The results will be reported as consistent with the administration of a steroid when the <sup>13</sup>C/<sup>12</sup>C value measured for the **metabolite(s)** differs significantly i.e. by 3 delta units or more from that of the urinary reference steroid chosen. In some *Samples*, the measure of the <sup>13</sup>C/<sup>12</sup>C value of the urinary reference steroid(s) may not be possible due to their low concentration. The results of such analysis will be reported as "inconclusive" unless the ratio measured for the metabolite(s) is below -28‰ based on non-derivatized steroid."

In this case, LNDD calculated this difference for all four testosterone metabolites tested. In so doing, LNDD compared the measures of androsterone and etiocholanolone to the urinary reference steroid 11-Ketoetio; and compared the measures of  $5\alpha$ Adiol and  $5\beta$ Adiol to the urinary reference steroid  $5\beta$ Pdiol. For reasons that are not stated, LNDD